<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:46:47Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10134004" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10134004</identifier>
        <datestamp>2023-04-28</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10134004</article-id>
              <article-id pub-id-type="pmcid">PMC10134004</article-id>
              <article-id pub-id-type="pmc-uid">10134004</article-id>
              <article-id pub-id-type="pmid">37099295</article-id>
              <article-id pub-id-type="pmid">37099295</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.10039</article-id>
              <article-id pub-id-type="publisher-id">zoi230323</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Infectious Diseases</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19</article-title>
                <subtitle>2 Randomized Clinical Trials</subtitle>
                <alt-title alt-title-type="headline">Tixagevimab-Cilgavimab Administered Intramuscularly or Intravenously for COVID-19</alt-title>
                <alt-title alt-title-type="running-head">Tixagevimab-Cilgavimab Administered Intramuscularly or Intravenously for COVID-19</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Bender Ignacio</surname>
                    <given-names>Rachel A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi230323aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi230323aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chew</surname>
                    <given-names>Kara W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MS</degrees>
                  <xref rid="zoi230323aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moser</surname>
                    <given-names>Carlee</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230323aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Currier</surname>
                    <given-names>Judith S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MSc</degrees>
                  <xref rid="zoi230323aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eron</surname>
                    <given-names>Joseph J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230323aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Javan</surname>
                    <given-names>Arzhang Cyrus</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <degrees>DTM&amp;H</degrees>
                  <xref rid="zoi230323aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Giganti</surname>
                    <given-names>Mark J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230323aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Aga</surname>
                    <given-names>Evgenia</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi230323aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gibbs</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230323aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tchouakam Kouekam</surname>
                    <given-names>Herv√©</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="zoi230323aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Johnsson</surname>
                    <given-names>Eva</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230323aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Esser</surname>
                    <given-names>Mark T.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <degrees>MBA</degrees>
                  <xref rid="zoi230323aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoover</surname>
                    <given-names>Keila</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230323aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Neytman</surname>
                    <given-names>Gene</given-names>
                  </name>
                  <degrees>DO</degrees>
                  <xref rid="zoi230323aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Newell</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <degrees>RN</degrees>
                  <xref rid="zoi230323aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Daar</surname>
                    <given-names>Eric S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230323aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fischer</surname>
                    <given-names>William</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230323aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fletcher</surname>
                    <given-names>Courtney V.</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <xref rid="zoi230323aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Jonathan Z.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MMSc</degrees>
                  <xref rid="zoi230323aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Greninger</surname>
                    <given-names>Alexander L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230323aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coombs</surname>
                    <given-names>Robert W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230323aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hughes</surname>
                    <given-names>Michael D.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230323aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Davey</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MAS</degrees>
                  <xref rid="zoi230323aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wohl</surname>
                    <given-names>David Alain</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230323aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <on-behalf-of>for the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)‚Äì2/A5401 Study Team</on-behalf-of>
              </contrib-group>
              <aff id="zoi230323aff1"><label>1</label>Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle</aff>
              <aff id="zoi230323aff2"><label>2</label>Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington</aff>
              <aff id="zoi230323aff3"><label>3</label>Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles)</aff>
              <aff id="zoi230323aff4"><label>4</label>Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts</aff>
              <aff id="zoi230323aff5"><label>5</label>Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill</aff>
              <aff id="zoi230323aff6"><label>6</label>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</aff>
              <aff id="zoi230323aff7"><label>7</label>Vaccines &amp; Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Cambridge, United Kingdom</aff>
              <aff id="zoi230323aff8"><label>8</label>Vaccines &amp; Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Toronto, Ontario, Canada</aff>
              <aff id="zoi230323aff9"><label>9</label>Vaccines &amp; Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden</aff>
              <aff id="zoi230323aff10"><label>10</label>Vaccines &amp; Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland</aff>
              <aff id="zoi230323aff11"><label>11</label>Miami Clinical Research and Baptist Health South Florida, Miami</aff>
              <aff id="zoi230323aff12"><label>12</label>Quantum Clinical Trials, Miami Beach, Florida</aff>
              <aff id="zoi230323aff13"><label>13</label>Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, California</aff>
              <aff id="zoi230323aff14"><label>14</label>Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina School of Medicine, Chapel Hill</aff>
              <aff id="zoi230323aff15"><label>15</label>UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha</aff>
              <aff id="zoi230323aff16"><label>16</label>Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, Massachusetts</aff>
              <aff id="zoi230323aff17"><label>17</label>Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle</aff>
              <aff id="zoi230323aff18"><label>18</label>Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> February 26, 2023.</p>
                <p content-type="published-online"><bold>Published:</bold> April 26, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.10039</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. ¬© 2023 Bender Ignacio RA et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi230323cor1"><bold>Corresponding Author:</bold> Rachel A. Bender Ignacio, MD, MPH, UW Positive Research, Harborview Medical Center, 325 Ninth Ave, Box 359929, Seattle, WA 98104 (<email xlink:href="rbi13@uw.edu">rbi13@uw.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Mr Tchouakam Kouekam had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Bender Ignacio and Chew contributed equally as co‚Äìfirst authors. Drs Smith and Wohl contributed equally as senior authors.</p>
                <p><italic>Concept and design:</italic> Bender Ignacio, Chew, Moser, Javan, Johnsson, Newell, Daar, Fischer, Fletcher, Li, Coombs, Hughes, Smith, Wohl.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Bender Ignacio, Chew, Moser, Currier, Eron, Javan, Giganti, Aga, Gibbs, Tchouakam Kouekam, Johnsson, Esser, Hoover, Neytman, Fletcher, Li, Greninger, Coombs, Hughes, Smith, Wohl.</p>
                <p><italic>Drafting of the manuscript:</italic> Bender Ignacio, Moser, Aga, Gibbs, Johnsson, Smith, Wohl.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Bender Ignacio, Chew, Moser, Currier, Eron, Javan, Giganti, Aga, Gibbs, Tchouakam Kouekam, Johnsson, Esser, Hoover, Neytman, Newell, Daar, Fischer, Fletcher, Li, Greninger, Coombs, Hughes, Smith, Wohl.</p>
                <p><italic>Statistical analysis:</italic> Moser, Giganti, Aga, Gibbs, Tchouakam Kouekam, Hughes.</p>
                <p><italic>Obtained funding:</italic> Chew, Currier, Eron, Daar, Hughes, Smith.</p>
                <p><italic>Administrative, technical, or material support:</italic> Chew, Currier, Javan, Johnsson, Esser, Neytman, Newell, Daar, Li, Greninger, Coombs, Smith, Wohl.</p>
                <p><italic>Supervision:</italic> Bender Ignacio, Chew, Currier, Eron, Gibbs, Johnsson, Esser, Daar, Fischer, Greninger, Smith, Wohl.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Bender Ignacio reported consulting for AbbVie Inc and Resverlogix Corps and receiving research support from Novartis AG and Acentage Pharma through her institution. Dr Chew reported receiving research funding to her institution from Merck &amp; Co Inc, and consulting for Pardes Biosciences Inc. Dr Currier reported consulting for Merck &amp; Co Inc. Dr Eron reported ad hoc consulting for GSK PLC/Vir Biotechnology Inc, and serving as the data monitoring committee chair for Attenuation of Disease Progression with Azilect Given Once-daily (ADAGIO) phase 3 studies. Dr Gibbs reported owing stock in AstraZeneca. Dr Esser reported owing stock in AstraZeneca. Dr Johnsson reported owning stock in AstraZeneca. Dr Daar reported consulting for Gilead Sciences Inc, Merck &amp; Co Inc, and GSK PLC/ViiV and receiving research support through his institution from Gilead Sciences Inc, and GSK PLC/ViiV. Dr Fischer reported receiving research funding to his institution from Ridgeback Biopharmaceuticals, serving on adjudication committees for Janssen Pharmaceuticals and Syneos Health, and consulting for F. Hoffmann‚ÄìLa Roche AG and Merck &amp; Co Inc. Dr Li reported consulting for AbbVie Inc and receiving research support from Merck &amp; Co Inc. Dr Greninger reported contract testing from Abbott Laboratories, Cepheid, Novavax Inc, Pfizer Inc, Janssen Pharmaceuticals, and Hologic Inc, and receiving research support from Gilead Sciences Inc, and Merck &amp; Co Inc, outside of the described work. Dr Smith reported consulting for Evidera, Fluxergy, Kiadis, Linear Therapies, Matrix BioMed Inc, Arena Pharmaceuticals Inc, VxBiosciences Inc, Model Medicines, Bayer AG, Signant Health, and Brio Clinical Inc. Dr Wohl reported receiving funding to his institution to support research from Gilead Sciences Inc, and Eli Lilly and Company and receiving honoraria for serving on the advisory board and consulting for Gilead Sciences Inc. No other conflicts were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by grants UM1AI068636, UM1AI068634, and UM1AI106701 from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The study drug was donated by AstraZeneca.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The study sponsor, the NIH Division of AIDS, participated in the design of the study and reviewed and approved the protocol prior to study initiation. Oversight and responsibility for data collection was delegated by the sponsor to PPD Inc, a contract research organization. Safety laboratories were measured at PPD Laboratory Services Global Central Labs, and statistical analyses were performed by Everest Clinical Research under contract with AstraZeneca and the AIDS Clinical Trial Group (ACTG) Statistical and Data Analysis Center (SDAC) according to the statistical analysis plan developed by the SDAC, with final analyses reviewed by SDAC. A sponsor representative (Dr Javan) reviewed and approved the manuscript.</p>
                <p><bold>Group Information:</bold> Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)‚Äì2/A5401 Study Team, site investigators, and their study site funding are listed in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 4</xref>.</p>
                <p><bold>Additional Contributions:</bold> We thank the study participants, site staff, site investigators, and the entire ACTIV-2/A5401 Study Team; the ACTG, including Lara Hosey, MA, Jhoanna Roa, MD, and Nilam Patel, MPH, DLH Corporation; the UW Virology Specialty Laboratory, including Emily Degli-Angeli, MLS, Erin Goecker, MS, Glenda Daza, MLS, Socorro Harb, MLS, and Joan Dragavon, MLS; the ACTG Laboratory Center, including Grace Aldrovandi, MD, and William Murtaugh, MPH; Frontier Science, including Marlene Cooper, MS, Howard Gutzman, BS, Kevin Knowles, PhD, and Rachel Bowman, PhD; the Harvard Center for Biostatistics in AIDS Research and ACTG SDAC; the ACTIV-2 Community Advisory Board; the NIAID Division of AIDS, including Bill Erhardt, MD, Lorraine Waring, BSc, and Diane Hessinger, MBA; the Foundation for the NIH and the ACTIV partnership, including Stacey Adam, PhD; and the PPD clinical research business of Thermo Fisher Scientific. We also thank the members of the ACTIV-2/A5401 data and safety monitoring board, including Graeme A. Meintjes, PhD, MBChB (chair), Barbara E. Murray, MD, Stuart Campbell Ray, MD, Valeria Cavalcanti Rolla, MD, PhD, Haroon Saloojee, MB BCh, MSc, Anastasios A. Tsiatis, PhD, Paul A. Volberding, MD, Jonathan Kimmelman, PhD, David Glidden, PhD, and Sally Hunsberger, PhD (executive secretary).</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-04-26T10:00">
                <day>26</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>26</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>6</volume>
              <issue>4</issue>
              <elocation-id>e2310039</elocation-id>
              <history>
                <date date-type="received">
                  <day>21</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>26</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Bender Ignacio RA et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2310039.pdf">jamanetwopen-e2310039.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.10039"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi230323-1">
                  <title>Question</title>
                  <p>Do tixagevimab and cilgavimab, 2 long-acting anti‚ÄìSARS-CoV-2 monoclonal antibodies given in combination, improve symptoms and viral shedding when administered intramuscularly in the thigh or intravenously in persons with early COVID-19?</p>
                </sec>
                <sec id="ab-zoi230323-2">
                  <title>Findings</title>
                  <p>In these 2 phase 2 randomized clinical trials within the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)‚Äì2/A5401 platform, tixagevimab-cilgavimab given intramuscularly or intravenously was safe but did not shorten symptom duration. Fewer participants who received intramuscular treatment vs placebo had quantifiable SARS-CoV-2 RNA in nasopharyngeal swabs at day 7.</p>
                </sec>
                <sec id="ab-zoi230323-3">
                  <title>Meaning</title>
                  <p>Tixagevimab-cilgavimab produced modest antiviral effects, suggesting potential clinical activity for treatment of SARS-CoV-2 infection, but had no effect on symptom duration.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>These 2 phase 2 randomized clinical trials evaluated the safety and efficacy of single-dose combination tixagevimab and cilgavimab administered intramuscularly and intravenously, each compared with placebo, for treatment of symptomatic nonhospitalized adults with early COVID-19.</p>
              </abstract>
              <abstract>
                <sec id="ab-zoi230323-4">
                  <title>Importance</title>
                  <p>Development of effective, scalable therapeutics for SARS-CoV-2 is a priority.</p>
                </sec>
                <sec id="ab-zoi230323-5">
                  <title>Objective</title>
                  <p>To test the efficacy of combined tixagevimab and cilgavimab monoclonal antibodies for early COVID-19 treatment.</p>
                </sec>
                <sec id="ab-zoi230323-6">
                  <title>Design, Setting, and Participants</title>
                  <p>Two phase 2 randomized blinded placebo-controlled clinical trials within the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)‚Äì2/A5401 platform were performed at US ambulatory sites. Nonhospitalized adults 18 years or older within 10 days of positive SARS-CoV-2 test and symptom onset were eligible and were enrolled from February 1 to May 31, 2021.</p>
                </sec>
                <sec id="ab-zoi230323-7">
                  <title>Interventions</title>
                  <p>Tixagevimab-cilgavimab, 300 mg (150 mg of each component) given intravenously (IV) or 600 mg (300 mg of each component) given intramuscularly (IM) in the lateral thigh, or pooled placebo.</p>
                </sec>
                <sec id="ab-zoi230323-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Coprimary outcomes were time to symptom improvement through 28 days; nasopharyngeal SARS-CoV-2 RNA below the lower limit of quantification (LLOQ) on days 3, 7, or 14; and treatment-emergent grade 3 or higher adverse events through 28 days.</p>
                </sec>
                <sec id="ab-zoi230323-9">
                  <title>Results</title>
                  <p>A total of 229 participants were randomized for the IM study and 119 were randomized for the IV study. The primary modified intention-to-treat population included 223 participants who initiated IM tixagevimab-cilgavimab (n‚Äâ=‚Äâ106) or placebo treatment (n‚Äâ=‚Äâ117) (median age, 39 [IQR, 30-48] years; 113 [50.7%] were men) and 114 who initiated IV tixagevimab-cilgavimab (n‚Äâ=‚Äâ58) or placebo treatment (n‚Äâ=‚Äâ56) (median age, 44 [IQR, 35-54] years; 67 [58.8%] were women). Enrollment in the IV study was stopped early based on a decision to focus on IM product development. Participants were enrolled at a median of 6 (IQR, 4-7) days from COVID-19 symptom onset. Significant differences in time to symptom improvement were not observed for IM tixagevimab-cilgavimab vs placebo or IV tixagevimab-cilgavimab vs placebo. A greater proportion in the IM tixagevimab-cilgavimab arm (69 of 86 [80.2%]) than placebo (62 of 96 [64.6%]) had nasopharyngeal SARS-CoV-2 RNA below LLOQ at day 7 (adjusted risk ratio, 1.33 [95% CI, 1.12-1.57]) but not days 3 and 14; the joint test across time points favored treatment (<italic>P</italic>‚Äâ=‚Äâ.003). Differences in the proportion below LLOQ were not observed for IV tixagevimab-cilgavimab vs placebo at any of the specified time points. There were no safety signals with either administration route.</p>
                </sec>
                <sec id="ab-zoi230323-10">
                  <title>Conclusions</title>
                  <p>In these 2 phase 2 randomized clinical trials, IM or IV tixagevimab-cilgavimab was safe but did not change time to symptom improvement. Antiviral activity was more evident in the larger IM trial.</p>
                </sec>
                <sec id="ab-zoi230323-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04518410" ext-link-type="uri">NCT04518410</ext-link></p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI230323">
              <title>Introduction</title>
              <p>The COVID-19 pandemic caused by SARS-CoV-2 continues, and therapies that prevent hospitalization and/or death have received US Food and Drug Administration emergency use authorization, including monoclonal antibodies (mAbs) and direct-acting antivirals.<sup><xref rid="zoi230323r1" ref-type="bibr">1</xref>,<xref rid="zoi230323r2" ref-type="bibr">2</xref>,<xref rid="zoi230323r3" ref-type="bibr">3</xref>,<xref rid="zoi230323r4" ref-type="bibr">4</xref>,<xref rid="zoi230323r5" ref-type="bibr">5</xref>,<xref rid="zoi230323r6" ref-type="bibr">6</xref>,<xref rid="zoi230323r7" ref-type="bibr">7</xref></sup> Given 1-time dosing, safety in those with liver or kidney disease, and lack of drug-drug interactions, mAbs have been relied on to treat persons at risk for severe COVID-19, especially those for whom currently available oral agents are contraindicated. To date, all mAbs authorized for COVID-19 treatment have been delivered intravenously (IV); alternative administration routes for mAbs, including intramuscular (IM) injection, could improve treatment access.</p>
              <p>AZD7442 is a combination of 2 anti‚ÄìSARS-CoV-2 mAbs, tixagevimab (AZD8895) and cilgavimab (AZD1061), both derived from persons recovered from COVID-19. Tixagevimab-cilgavimab administered by IM gluteal injection previously received a US Food and Drug Administration emergency use authorization for preexposure prophylaxis.<sup><xref rid="zoi230323r8" ref-type="bibr">8</xref>,<xref rid="zoi230323r9" ref-type="bibr">9</xref></sup> These mAbs bind unique, nonoverlapping epitopes at the human angiotensin-converting enzyme 2 interface of the receptor-binding domain of the SARS-CoV-2 spike protein. Modifications in Fc regions were designed to extend their half-life to approximately 90 days and reduce risk of antibody-dependent enhancement.<sup><xref rid="zoi230323r10" ref-type="bibr">10</xref>,<xref rid="zoi230323r11" ref-type="bibr">11</xref>,<xref rid="zoi230323r12" ref-type="bibr">12</xref>,<xref rid="zoi230323r13" ref-type="bibr">13</xref>,<xref rid="zoi230323r14" ref-type="bibr">14</xref>,<xref rid="zoi230323r15" ref-type="bibr">15</xref></sup> The combination mAb demonstrated in vitro neutralization of SARS-CoV-2, with reduced activity against several Omicron subvariants.<sup><xref rid="zoi230323r16" ref-type="bibr">16</xref>,<xref rid="zoi230323r17" ref-type="bibr">17</xref>,<xref rid="zoi230323r18" ref-type="bibr">18</xref>,<xref rid="zoi230323r19" ref-type="bibr">19</xref></sup> We herein evaluated the safety and efficacy of single-dose combination tixagevimab-cilgavimab administered IM and IV, each compared with placebo, for treatment of symptomatic nonhospitalized adults with early COVID-19 within the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)‚Äì2 platform trial.</p>
            </sec>
            <sec id="H1-2-ZOI230323">
              <title>Methods</title>
              <sec id="H2-1-ZOI230323">
                <title>Trial Design and Oversight</title>
                <p>ACTIV-2/A5401 is a multicenter, controlled platform randomized clinical trial designed to evaluate investigational agents for treatment of nonhospitalized adults with mild-to-moderate COVID-19. The trial protocol is provided in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 1</xref>. The protocol was approved by a central institutional review board, with additional local approval as required by sites. Participants provided written informed consent. The study followed the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline.</p>
                <p>Tixagevimab-cilgavimab administered IV and IM were studied as separate agents, and each group was enrolled in parallel and compared with placebo. Participants were randomized in 2 steps to an investigational agent group (eg, IM tixagevimab-cilgavimab, IV tixagevimab-cilgavimab, or another agent in the platform), and then to blinded active agent or placebo for that agent, within the assigned group. For each investigational agent, a control arm was constructed by pooling all participants who were eligible for that agent group and randomized to placebo for that agent or any other concurrently enrolling agent. Randomization was stratified by time from symptom onset (‚â§5 or &gt;5 days) and risk of disease progression (lower or higher). Details on trial design, including randomization scheme, are given in eMethods 1 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p>
                <p>Each phase 2 evaluation was powered on the primary virologic outcome. The target sample size for each phase 2 evaluation was 220 (110 each for active agent and placebo), affording at least 82% power to detect a 20% absolute increase in proportion with viral RNA below the lower limit of quantification vs placebo, with 2-sided 5% type I error.</p>
              </sec>
              <sec id="H2-2-ZOI230323">
                <title>Participants and Procedures</title>
                <p>Eligible participants were nonhospitalized adults 18 years or older with symptomatic SARS-CoV-2 infection documented by positive antigen or nucleic acid testing results and symptom onset within 10 days of entry; early in enrollment, eligibility was further restricted to 8 days of symptoms as more data on the kinetics of SARS-CoV-2 became available.<sup><xref rid="zoi230323r20" ref-type="bibr">20</xref></sup> Eligibility for IV tixagevimab-cilgavimab was restricted to participants at higher risk of progression to severe COVID-19 based on protocol-defined age and comorbidities criteria; IM-eligible participants could be at lower or higher risk. Persons needing hospitalization or who had received investigational SARS-CoV-2 treatments or convalescent plasma were excluded. Enrollment into both tixagevimab-cilgavimab groups was limited to US sites (eMethods 2 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                <p>Participants self-reported their race and ethnicity (Asian, Black, Hispanic or Latino, White, or other race or ethnicity [including American Indian or Alaska Native, multiple races or ethnicities, or other race or ethnicity]) and gender (cisgender, transgender spectrum, or not reported). These data were collected in accordance with reporting requirements for clinical trials and to ensure representation among the study participants.</p>
                <p>On day 0, participants randomized to the IM group received 600 mg of tixagevimab-cilgavimab (300 mg in 3 mL of each component, 1 component delivered to each lateral thigh [IM T-C arm]), or equivalent volumes of IM saline placebo. Participants in the IV group received 300 mg of tixagevimab-cilgavimab (150 mg of each component admixed [IV T-C arm]) or saline placebo infused over approximately 15 minutes. Visits were conducted at days 3, 7, 14, and 28 for clinical assessments and staff-collected nasopharyngeal swabs. Participants self-collected anterior nasal swabs daily through day 14 and completed a daily symptom diary through day 28.<sup><xref rid="zoi230323r20" ref-type="bibr">20</xref></sup></p>
              </sec>
              <sec id="H2-3-ZOI230323">
                <title>Study Objectives and Outcome Measures</title>
                <p>The 3 primary outcomes were (1) time to symptom improvement through 28 days; (2) SARS-CoV-2 RNA below the lower limit of quantification (LLOQ; 2.0 log<sub>10</sub> copies/mL) on nasopharyngeal samples at days 3, 7, or 14; and (3) new grade 3 or higher treatment-emergent adverse events (TEAEs) through day 28. Time to symptom improvement was defined as days from entry to the first of 2 consecutive days when all 13 targeted symptoms scored as moderate or severe at study entry were scored as mild or absent, and all symptoms scored as mild or absent at entry were scored as absent. Key secondary outcomes through day 28 included time to symptom resolution (time to the first of 2 consecutive days when all targeted symptoms were reported absent), progression of 1 or more targeted symptoms to a worse severity than at entry, time to self-reported return to usual health, time-averaged total daily symptom score, the composite of all-cause hospitalization or death, quantitative nasopharyngeal SARS-CoV-2 RNA levels, and SARS-CoV-2 RNA below the LLOQ on anterior nasal swabs through day 14. Virologic methods were previously published.<sup><xref rid="zoi230323r20" ref-type="bibr">20</xref></sup></p>
              </sec>
              <sec id="H2-4-ZOI230323">
                <title>Statistical Analysis</title>
                <p>Analyses were restricted to the modified intention-to-treat population, defined as all randomized participants who initiated the study intervention. Time to symptom improvement, symptom resolution, and return to usual health were compared between arms using the Gehan-Wilcoxon test for censored data. Time-averaged total daily symptom score was compared using a 2-sided Wilcoxon rank sum test.</p>
                <p>The proportion of participants with nasopharyngeal and anterior nasal SARS-CoV-2 RNA less than the LLOQ was compared between arms across study visits using Poisson regression with robust variance adjusted for entry log<sub>10</sub> transformed SARS-CoV-2 RNA level, summarized with risk ratios (RRs) and 95% CIs and joint Wald test across the time points. Quantitative nasopharyngeal SARS-CoV-2 RNA levels at each postentry visit were compared between arms using Wilcoxon rank sum tests. Post hoc analysis was conducted to examine changes in nasopharyngeal RNA from day 0 among participants with quantifiable day 0 nasopharyngeal RNA using linear regression models for censored data, adjusting for baseline RNA level.</p>
                <p>The proportion of participants experiencing a new grade 3 or greater TEAE through day 28 and the proportion with symptom progression were compared between arms using log-binomial regression and summarized with an RR and <italic>P</italic> value based on the Wald test. The proportion of hospitalizations and/or deaths through day 28 was compared between arms using a Fisher exact test.</p>
                <p>All comparisons used a 2-sided 5% type I error without adjustment for multiple comparisons; <italic>P</italic> &lt; .05 indicated statistical significance. Statistical analyses were conducted with SAS software, version 9.4 (SAS Institute Inc). The ACTIV-2 statistical analysis plan is available in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI230323">
              <title>Results</title>
              <sec id="H2-5-ZOI230323">
                <title>Study Population</title>
                <p>Between February 1 and May 31, 2021, 228 participants were randomized to the IM T-C arm or pooled placebo; 223 (106 to active treatment and 117 to placebo) initiated study intervention and were included in the modified intention-to-treat analysis (CONSORT diagram in eFigure, A, in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). Of the 119 participants randomized to the IV T-C arm or pooled placebo, 114 (58 to active treatment and 56 to placebo) initiated study intervention and were included in the modified intention-to-treat analysis (CONSORT diagram in eFigure, B, in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). Baseline characteristics are described in <xref rid="zoi230323t1" ref-type="table">Table 1</xref>. The median age was 39 (IQR, 30-48) years in the IM trial, with 12 of 223 (5.4%) 60 years or older (110 [49.3%] women and 113 [50.7%] men). In terms of race and ethnicity, 3 participants in the IM trial (1.3%) were Asian, 26 (11.7%) were Black, 99 (44.4%) were Hispanic or Latino, 181 (81.2%) were White, and 12 (5.4%) were of other race or ethnicity (including American Indian or Alaska Native, multiple races or ethnicities, or other race or ethnicity). Participants in the IV trial had a median age of 44 (IQR, 35-44) years, with 17 of 114 (14.9%)‚Äâ60 years or older (67 [58.8%] women and 47 [41.2%] men). For self-reported race and ethnicity, 1 participant in the IV trial (0.9%) was Asian, 22 (19.3%) were Black, 54 (47.4%) were Hispanic or Latino, 89 (78.1%) were White, and 2 (1.8%) were of other race or ethnicity. Only 13 participants in the IM trial (5.8%) and 1 in the IV trial (0.9%) reported receiving at least 1 COVID-19 vaccine dose prior to entry. Overall, 100 participants in the IM trial (44.8%) and 45 in the IV trial (39.5%) enrolled within 5 days of symptom onset. Enrollment into the IV trial was stopped early following a decision by the manufacturer to focus on development of IM administration of tixagevimab-cilgavimab due to evolving standards of COVID-19 treatment; there were no safety concerns.</p>
                <table-wrap position="float" id="zoi230323t1">
                  <label>Table 1. </label>
                  <caption>
                    <title>Demographics of Participants Receiving IM or IV Tixagevimab-Cilgavimab and Their Respective Pooled Placebo Arms</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="17.56%" span="1"/>
                    <col width="13.74%" span="1"/>
                    <col width="13.74%" span="1"/>
                    <col width="13.74%" span="1"/>
                    <col width="13.74%" span="1"/>
                    <col width="13.74%" span="1"/>
                    <col width="13.74%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="3" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="6" valign="top" align="left" scope="colgroup" rowspan="1">Tixagevimab-cilgavimab trial<xref rid="zoi230323t1n1" ref-type="table-fn"><sup>a</sup></xref></th>
                      </tr>
                      <tr>
                        <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">IM administration</th>
                        <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">IV administration</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">T-C (n‚Äâ=‚Äâ106)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n‚Äâ=‚Äâ117)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">All (n‚Äâ=‚Äâ223)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">T-C (n‚Äâ=‚Äâ58)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n‚Äâ=‚Äâ56)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">All (n‚Äâ=‚Äâ114)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, median (IQR), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40 (32-48)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 (29-48)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 (30-48)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43 (33-51)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">46 (35-58)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">44 (35-54)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Women</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52 (49.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58 (49.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">110 (49.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">34 (58.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (58.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67 (58.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Men</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54 (50.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">59 (50.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">113 (50.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (41.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (41.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47 (41.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Gender<xref rid="zoi230323t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cisgender</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">105 (99.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">116 (99.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">221 (99.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58 (100)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">56 (100)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">114 (100)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Transgender spectrum</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not reported</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race<xref rid="zoi230323t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (7.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">18 (15.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26 (11.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (17.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (21.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 (19.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">88 (83.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">93 (79.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">181 (81.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47 (81.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">42 (75.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">89 (78.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="zoi230323t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (6.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (4.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (5.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (3.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity<xref rid="zoi230323t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic or Latino</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52 (49.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47 (40.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">99 (44.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (46.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (48.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54 (47.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not Hispanic or Latino</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54 (50.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">70 (59.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">124 (55.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (53.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29 (51.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">60 (52.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, median (IQR)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">28 (25-33)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">28 (25-32)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">28 (25-32)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">34 (26-37)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (27-36)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (27-37)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Duration of symptoms prior to entry, d</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4-7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4-7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4-7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (3-7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4-7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4-7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ‚â§5</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47 (44.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 (45.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">100 (44.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (36.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (42.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45 (39.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">COVID-19 progression risk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (31.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (28.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66 (29.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58 (100)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">56 (100)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">114 (100)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lower</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">73 (68.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">84 (71.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">157 (70.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of SARS-CoV-2 vaccination</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9 (8.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (3.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.7)<xref rid="zoi230323t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IM, intramuscularly; IV, intravenously; T-C, study group receiving active treatment with tixagevimab-cilgavimab.</p>
                    <fn id="zoi230323t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Unless otherwise indicated, data are expressed as No. (%) of participants. Percentages have been rounded and may not total 100. All participants were from sites in the US. IM administration consists of 600 mg (300 mg of each component) of monoclonal antibodies or 600 mg of placebo; IV administration, 300 mg (150 mg of each component) of monoclonal antibodies or 300 mg of placebo.</p>
                    </fn>
                    <fn id="zoi230323t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Self-identified by participants.</p>
                    </fn>
                    <fn id="zoi230323t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Includes American Indian or Alaska Native, multiple races or ethnicities, and other race or ethnicity.</p>
                    </fn>
                    <fn id="zoi230323t1n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>For most study enrollment into both IM and IV groups, persons who had received SARS-CoV-2 vaccines were considered lower risk. The single IV participant who was vaccinated enrolled under Protocol V3.0, when having received a vaccine was not included in risk stratification.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Variant analysis was available for 202 participants in either the IV or IM trials: 115 (56.9%) had the Alpha variant, 23 (11.4%) had the Iota variant, 1 (0.5%) had the Delta variant, and 63 (31.2%) had a mix of other variants (eTable 7 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). In the IM trial, 211 (94.6%) remained on study through day 28, as did 108 (94.7%) in the IV trial.</p>
              </sec>
              <sec id="H2-6-ZOI230323">
                <title>Clinical Outcomes</title>
                <sec id="H3-1-ZOI230323">
                  <title>IM Tixagevimab-Cilgavimab Trial</title>
                  <p>Time to symptom improvement was not significantly different between arms, with a median of 8 (95% CI, 7-12) days for IM T-C and 10 (95% CI, 8-13) days for placebo (<italic>P</italic>‚Äâ=‚Äâ.35) (<xref rid="zoi230323f1" ref-type="fig">Figure 1</xref>A and eTable 1 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). The effects were similar for participants enrolled within 5 days vs more than 5 days after symptom onset (eTable 2 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). Median time to return to health was 14 (95% CI, 8-16) days for the IM T-C arm and 13 (95% CI, 11-16) days for the placebo arm (<italic>P</italic>‚Äâ=‚Äâ.79) (<xref rid="zoi230323f1" ref-type="fig">Figure 1</xref>B), and there was no difference in total daily symptom scores through day 28 (median area under the curve, 2.2 [IQR, 1.1-4.3] for T-C vs 2.2 [IQR, 1.1-4.1] for placebo; <italic>P</italic>‚Äâ=‚Äâ.87) (eTable 1 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). Four persons (3.8%) were hospitalized in the IM T-C arm and 7 (6.0%) in the placebo arm in the first 28 days (<italic>P</italic>‚Äâ=‚Äâ.54); there were no deaths in either arm (<xref rid="zoi230323t2" ref-type="table">Table 2</xref>).</p>
                  <fig position="float" id="zoi230323f1" fig-type="figure">
                    <label>Figure 1. </label>
                    <caption>
                      <title>Time to Symptom Improvement and Return to Usual Health</title>
                      <p>Participants include those treated with a tixagevimab-cilgavimab (T-C) combination administered as 600 mg intramuscularly (IM) or placebo or as 300 mg intravenously (IV) or placebo.</p>
                    </caption>
                    <graphic xlink:href="jamanetwopen-e2310039-g001" position="float"/>
                  </fig>
                  <table-wrap position="float" id="zoi230323t2">
                    <label>Table 2. </label>
                    <caption>
                      <title>Adverse Events in IM and IV T-C Groups</title>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col width="14.97%" span="1"/>
                      <col width="9.53%" span="1"/>
                      <col width="10.2%" span="1"/>
                      <col width="14.97%" span="1"/>
                      <col width="7.48%" span="1"/>
                      <col width="10.2%" span="1"/>
                      <col width="10.2%" span="1"/>
                      <col width="14.97%" span="1"/>
                      <col width="7.48%" span="1"/>
                      <thead>
                        <tr>
                          <th rowspan="3" valign="top" align="left" scope="col" colspan="1">Adverse event</th>
                          <th colspan="8" valign="top" align="left" scope="colgroup" rowspan="1">Tixagevimab-cilgavimab trial<xref rid="zoi230323t2n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        </tr>
                        <tr>
                          <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">IM administration</th>
                          <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">IV administration</th>
                        </tr>
                        <tr>
                          <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">T-C (n‚Äâ=‚Äâ106)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n‚Äâ=‚Äâ117)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Risk ratio (95% CI)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230323t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">T-C (n‚Äâ=‚Äâ58)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n‚Äâ=‚Äâ56)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Risk ratio (95% CI)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230323t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Treatment emergent</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Grade 3 or higher through day 28<xref rid="zoi230323t2n3" ref-type="table-fn"><sup>c</sup></xref>
</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">9 (8.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (6.0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.42 (0.55-3.68)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.47</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3 (5.2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (12.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0.41 (0.11-1.52)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.18</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Grade 2 or higher through day 28</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">30 (28.3)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">25 (21.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.33 (0.84-2.01)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.23</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">20 (34.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">15 (26.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.29 (0.74-2.24)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.38</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Serious<xref rid="zoi230323t2n4" ref-type="table-fn"><sup>d</sup></xref></td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> All through day 28</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (3.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (6.0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0 </td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (7.1)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> COVID-19 pneumonia</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (3.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6 (5.1)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3 (5.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gastroenteritis</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (0.)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pneumonia bacteria</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (1.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Acute respiratory failure</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (1.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Study drug‚Äìrelated</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (6.6)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">11 (9.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (6.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6 (1.7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Special interest through day 28</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (3.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (1.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypersensitivity</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IRR</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (3.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (1.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>Abbreviations: IM, intramuscularly; IRR, infusion related reaction; IV, intravenously; NA, not applicable; T-C, study group receiving active treatment with tixagevimab-cilgavimab.</p>
                      <fn id="zoi230323t2n1">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>Unless otherwise indicated, data are expressed as No. (%) of participants. IM administration consists of 600 mg (300 mg of each component) of monoclonal antibody or 600 mg of placebo; IV administration, 300 mg (150 mg of each component) of monoclonal antibody or 300 mg of placebo.</p>
                      </fn>
                      <fn id="zoi230323t2n2">
                        <label>
                          <sup>b</sup>
                        </label>
                        <p>Calculated using Wald test from Poisson regression with robust variance and log-link; risk ratio comparing T-C group vs placebo.</p>
                      </fn>
                      <fn id="zoi230323t2n3">
                        <label>
                          <sup>c</sup>
                        </label>
                        <p>Indicates primary outcome.</p>
                      </fn>
                      <fn id="zoi230323t2n4">
                        <label>
                          <sup>d</sup>
                        </label>
                        <p>All serious adverse events were hospitalizations. There were no deaths in either study. None of the hospitalizations were considered to be study drug related and were primarily progression of COVID-19 respiratory failure.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="H3-2-ZOI230323">
                  <title>IV Tixagevimab-Cilgavimab Trial</title>
                  <p>Time to symptom improvement was similar between IV trial arms with a median of 11 (95% CI, 9-15) days for IV T-C and 10 (95% CI, 7-15) days for placebo (<italic>P</italic>‚Äâ=‚Äâ.71) (<xref rid="zoi230323f1" ref-type="fig">Figure 1</xref>C and eTable 1 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). The median time to return to health was 12 (95% CI, 8-16) days for the IV T-C arm and 15 (95% CI, 9-19) days for the placebo arm (<italic>P</italic>‚Äâ=‚Äâ.51) (<xref rid="zoi230323f1" ref-type="fig">Figure 1</xref>D). There was no between-arm difference in time-averaged total daily symptom scores through day 28 (median area under the curve, 2.6 [IQR, 1.2-4.2] for T-C vs 2.2 [IQR, 1.3-5.2] for placebo; <italic>P</italic>‚Äâ&gt; .99) (eTable 1 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). There were no hospitalizations in the IV T-C arm and 4 (7.1%) in the placebo arm during the first 28 days (<italic>P</italic>‚Äâ=‚Äâ.06), and no deaths in either arm (<xref rid="zoi230323t2" ref-type="table">Table 2</xref>).</p>
                </sec>
              </sec>
              <sec id="H2-7-ZOI230323">
                <title>Virologic Outcomes</title>
                <sec id="H3-3-ZOI230323">
                  <title>IM Tixagevimab-Cilgavimab Trial</title>
                  <p>The proportion of participants with unquantifiable nasopharyngeal SARS-CoV-2 RNA differed significantly across days 3, 7, and 14 between the IM T-C and placebo arms after adjusting for pretreatment (day 0) values (joint <italic>P</italic>‚Äâ=‚Äâ.003) (<xref rid="zoi230323t3" ref-type="table">Table 3</xref>). This primarily reflected a higher proportion in the IM T-C arm (69 of 86 [80.2%]) than the placebo arm (62 of 96 [64.6%]) with SARS-CoV-2 RNA below LLOQ at day 7 (adjusted RR, 1.33 [95% CI, 1.12-1.57]). At day 3 the proportion with SARS-CoV-2 RNA below LLOQ was 28 of 85 participants (32.9%) in the IM T-C arm vs 39 of 92 (42.4%) in the placebo arm (adjusted RR, 0.75 [95% CI, 0.52-1.10]), and at day 14 it was 71 of 83 (85.5%) in the IM T-C arm vs 85 of 95 (89.5%) in the placebo arm (adjusted RR, 1.03 [95% CI, 0.90-1.18]) (<xref rid="zoi230323f2" ref-type="fig">Figure 2</xref>A). The difference in quantifiable virus at day 7 was observed in those enrolled both within and more than 5 days since symptom onset, although the estimated effect was greater in those enrolled within 5 days (eTable 3 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). Nasopharyngeal SARS-CoV-2 RNA levels did not differ between arms at any individual time point (<xref rid="zoi230323t3" ref-type="table">Table 3</xref>), and in a post hoc analysis the change in log<sub>10</sub> RNA from baseline to day 3 was not different between arms (<xref rid="zoi230323f2" ref-type="fig">Figure 2</xref>B and eTable 4 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>); later visits were not evaluated due to high levels of unquantifiable RNA. The proportion of participants with unquantifiable anterior nasal SARS-CoV-2 RNA across days 1 to 14 was different between the IM T-C and placebo arms (<italic>P</italic>‚Äâ=‚Äâ.01), with higher proportions below the LLOQ in the T-C arm on days 5 and 7 (eTable 5 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                  <table-wrap position="float" id="zoi230323t3">
                    <label>Table 3. </label>
                    <caption>
                      <title>Primary and Secondary Virologic Outcomes Among Persons Randomized to IM or IV T-C or Placebo</title>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col width="16.48%" span="1"/>
                      <col width="9.6%" span="1"/>
                      <col width="9.6%" span="1"/>
                      <col width="14.41%" span="1"/>
                      <col width="8.18%" span="1"/>
                      <col width="0.09%" span="1"/>
                      <col width="9.57%" span="1"/>
                      <col width="9.6%" span="1"/>
                      <col width="14.55%" span="1"/>
                      <col width="7.92%" span="1"/>
                      <thead>
                        <tr>
                          <th rowspan="3" valign="top" align="left" scope="col" colspan="1">Outcome</th>
                          <th colspan="9" valign="top" align="left" scope="colgroup" rowspan="1">Tixagevimab-cilgavimab trial</th>
                        </tr>
                        <tr>
                          <th colspan="5" valign="top" align="left" scope="colgroup" rowspan="1">IM administration<xref rid="zoi230323t3n1" ref-type="table-fn"><sup>a</sup></xref></th>
                          <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">IV administration<xref rid="zoi230323t3n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        </tr>
                        <tr>
                          <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">T-C (n‚Äâ=‚Äâ106)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n‚Äâ=‚Äâ117)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">aRR (95% CI)<xref rid="zoi230323t3n2" ref-type="table-fn"><sup>b</sup></xref></th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Overall <italic>P</italic> value<xref rid="zoi230323t3n3" ref-type="table-fn"><sup>c</sup></xref></th>
                          <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">T-C (n‚Äâ=‚Äâ58)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo (n‚Äâ=‚Äâ56)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">aRR (95% CI)<xref rid="zoi230323t3n2" ref-type="table-fn"><sup>b</sup></xref></th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Overall <italic>P</italic> value<xref rid="zoi230323t3n3" ref-type="table-fn"><sup>c</sup></xref></th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="10" valign="top" align="left" scope="col" rowspan="1">
                            <bold>Primary virology: proportion with nasopharyngeal SARS-CoV-2 RNA &lt;LLOQ</bold>
                          </td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">15 (17)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">22 (22)</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">NA</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">14 (29.2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">19 (38.0)</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">16</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">19</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">10</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Day 3</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td rowspan="9" valign="middle" align="left" colspan="1">.003</td>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td rowspan="9" valign="middle" align="left" colspan="1">.49</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">28 (32.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">39 (42.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0.75 (0.52 to 1.10)</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">26 (52.0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">24 (52.2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0.93 (0.69 to 1.26)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">21</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">25</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">8</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 7</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">69 (80.2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">62 (64.6)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.33 (1.12 to 1.57)</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">37 (74.0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">35 (71.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.12 (0.93 to 1.35)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">20</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">21</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">8</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 14</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">71 (85.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">85 (89.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.90 to 1.18)</td>
                          <td colspan="2" valign="top" align="left" rowspan="1">45 (95.7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">46 (93.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.10 (0.94 to 1.29)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">23</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">22</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">11</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td colspan="10" valign="top" align="left" scope="col" rowspan="1">
                            <bold>Secondary virology: quantitative nasopharyngeal SARS-CoV-2 RNA, log<sub>10</sub> copies/mL</bold>
                          </td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">5.43 (3.31 to 6.63)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4.67 (2.24 to 6.35)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">NA<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                          <td colspan="2" valign="top" align="left" rowspan="1">3.91 (&lt;LLOQ to 6.54)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3.00 (&lt;LLOQ to 5.87)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">NA<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">16</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">19</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">10</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 3</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.94 (&lt;LLOQ to 4.38)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.26 (&lt;LOD to 3.95)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">.17<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                          <td colspan="2" valign="top" align="left" rowspan="1">&lt;LLOQ (&lt;LOD to 3.94)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;LLOQ (&lt;LOD to 3.89)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">.96<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">21</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">25</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">8</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 7</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;LLOQ (&lt;LOD to &lt;LLOQ)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;LLOQ (&lt;LOD to 2.88)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">.31<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                          <td colspan="2" valign="top" align="left" rowspan="1">&lt;LOD (&lt;LOD to 2.20)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;LLOQ (&lt;LOD to 2.21)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">.46<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">20</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">21</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">8</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 14</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;LOD (&lt;LOD to &lt;LLOQ)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;LOD (&lt;LOD to &lt;LLOQ)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">.16<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                          <td colspan="2" valign="top" align="left" rowspan="1">&lt;LOD (&lt;LOD to &lt;LLOQ)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;LOD (&lt;LOD to &lt;LLOQ)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td rowspan="2" valign="middle" align="left" colspan="1">.90<xref rid="zoi230323t3n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. missing</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">23</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">22</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                          <td colspan="2" valign="top" align="left" rowspan="1">11</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7</td>
                          <td valign="top" align="left" rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>Abbreviations: aRR, adjusted risk ratio; LLOQ, lower limit of quantification (2.0 log<sub>10</sub> copies/mL); LOD, limit of detection (1.4 log<sub>10</sub> copies/mL); NA, not applicable; T-C, study group receiving active treatment with tixagevimab-cilgavimab.</p>
                      <fn id="zoi230323t3n1">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>IM administration consists of 600 mg (300 mg of each component) of monoclonal antibodies or 600 mg of placebo; IV administration, 300 mg (150 mg of each component) of monoclonal antibodies or 300 mg of placebo.</p>
                      </fn>
                      <fn id="zoi230323t3n2">
                        <label>
                          <sup>b</sup>
                        </label>
                        <p>Compares proportion of participants with SARS-CoV-2 RNA below LLOQ for tixagevimab-cilgavimab vs placebo, using a modified Poisson regression model adjusted for baseline log<sub>10</sub> SARS-CoV-2 RNA level, and an independent working correlation structure with robust SEs for repeated measurements. Corresponding 95% CI for the risk ratio from the generalized estimating equation fit.</p>
                      </fn>
                      <fn id="zoi230323t3n3">
                        <label>
                          <sup>c</sup>
                        </label>
                        <p>Calculated using the 2-sided Wald test.</p>
                      </fn>
                      <fn id="zoi230323t3n4">
                        <label>
                          <sup>d</sup>
                        </label>
                        <p>Calculated using the 2-sided Wilcoxon rank sum test.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <fig position="float" id="zoi230323f2" fig-type="figure">
                    <label>Figure 2. </label>
                    <caption>
                      <title>Virologic Outcomes of Tixagevimab-Cilgavimab (T-C) Treatment</title>
                      <p>Proportion of participants with SARS-CoV-2 RNA on nasopharyngeal swabs below the limit of detection (LOD [1.4 log<sub>10</sub> copies/mL]), at or above the LOD but below the lower limit of quantitation (LLOQ [2.0 log<sub>10</sub> copies/mL]), or with quantifiable SARS-CoV-2 RNA levels (‚â•LLOQ) on days 0, 3, 7, 14, and 28 by site-collected nasopharyngeal swab are shown for T-C treatment groups receiving 600 mg intramuscularly (IM) and 300 mg intravenously (IV). SARS-CoV-2 log<sub>10</sub> copies/mL levels in nasopharyngeal swabs for the T-C and placebo arms are shown at each of the same days in the IM and IV groups. B and D, Middle horizontal lines represent medians; outer horizontal lines of the boxes, IQRs; and whiskers, ranges.</p>
                    </caption>
                    <graphic xlink:href="jamanetwopen-e2310039-g002" position="float"/>
                  </fig>
                </sec>
                <sec id="H3-4-ZOI230323">
                  <title>IV Tixagevimab-Cilgavimab Trial</title>
                  <p>There were no significant differences in proportions with quantifiable nasopharyngeal SARS-CoV-2 RNA or quantitative levels at days 3, 7, or 14 (<xref rid="zoi230323t3" ref-type="table">Table 3</xref> and <xref rid="zoi230323f2" ref-type="fig">Figure 2</xref>C and D). The post hoc analysis for change in log<sub>10</sub> RNA from baseline to day 3 showed faster declines for the IV T-C compared with placebo arms (mean difference, ‚àí0.98 log<sub>10</sub> copies/mL [95% CI, ‚àí1.81 to ‚àí0.13 log<sub>10</sub> copies/mL]; <italic>P</italic>‚Äâ=‚Äâ.02) (eTable 4 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). Later visits were not evaluated due to high levels of unquantifiable RNA. Although there was no overall between-arm difference in the proportion with unquantifiable anterior nasal SARS-CoV-2 RNA across days 1 to 14, the IV T-C arm had a higher proportion with levels below LLOQ on days 5 and 6 (eTable 5 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                </sec>
              </sec>
              <sec id="H2-8-ZOI230323">
                <title>Safety</title>
                <sec id="H3-5-ZOI230323">
                  <title>IM Tixagevimab-Cilgavimab Trial</title>
                  <p>Grade 3 or higher TEAEs were reported in 9 participants (8.5%) in the IM T-C arm and 7 (6.0%) in the placebo arm (RR, 1.42 [95% CI, 0.55-3.68]; <italic>P</italic>‚Äâ=‚Äâ.47). Grade 2 or higher TEAEs were reported in 30 participants (28.3%) and 25 (21.4%) in the IM and placebo arms, respectively (<xref rid="zoi230323t2" ref-type="table">Table 2</xref> and eTable 6 in <xref rid="note-ZOI230323-1-s" ref-type="supplementary-material">Supplement 2</xref>). There were 11 serious adverse effects across both arms, but none were considered related to treatment. The arms had similar numbers of study drug‚Äìrelated adverse effects (7 [6.6%] vs 11 [9.4%]), and 1 participant in each arm had an adverse effect of special interest‚Äîa grade 2 hypersensitivity-type reaction in a tixagevimab-cilgavimab recipient and a grade 1 infusion-related reaction in a pooled placebo recipient; neither of these were serious. There were no moderate or severe injection site reactions.</p>
                </sec>
                <sec id="H3-6-ZOI230323">
                  <title>IV Tixagevimab-Cilgavimab Trial</title>
                  <p>Grade 3 or higher TEAEs occurred in 3 participants (5.2%) in the IV T-C arm and 7 (12.5%) in the placebo arm (RR,‚Äâ0.41 [95% CI, 0.11-1.52]; <italic>P</italic>‚Äâ=‚Äâ.18); grade 2 or higher TEAEs occurred in 20 (34.5%) and 15 (26.8%) participants, respectively. A similar number of study drug‚Äìrelated adverse events occurred in each arm (4 [6.9%] vs 6 [10.7%]), none of which were serious; there were 4 unrelated serious adverse events in the placebo arm. There were 2 infusion-related reactions in the IV T-C arm vs 1 in the placebo arm; all participants completed their infusion.</p>
                </sec>
              </sec>
            </sec>
            <sec id="H1-4-ZOI230323">
              <title>Discussion</title>
              <p>In these 2 phase 2 randomized clinical trials conducted prior to the emergence of the SARS-CoV-2 Delta and Omicron variants in a predominantly unvaccinated population with a median symptom duration of 6 days at the time of treatment, a single 600-mg IM dose of tixagevimab-cilgavimab to the thigh was safe but did not lead to improvement in symptom outcomes among adult outpatients with mild-to-moderate COVID-19 compared with placebo. Within the smaller group administered a 300-mg IV dose of tixagevimab-cilgavimab or placebo, there was a similar absence of benefit on symptoms. However, an antiviral effect of tixagevimab-cilgavimab is supported by the primary virologic analysis in the IM group and in secondary and post hoc analyses of both groups. There were fewer hospitalizations in both IM and IV T-C arms compared with placebo arms, but the study had limited power to evaluate effects.<sup><xref rid="zoi230323r21" ref-type="bibr">21</xref></sup></p>
              <p>Intramuscular tixagevimab-cilgavimab administered in the vastus lateralis muscle of the thigh was safe and well-tolerated. Absorption of drugs administered to the thigh is expected to be quicker with less interperson variability compared with injection into gluteal musculature, especially in women and those with higher body mass index.<sup><xref rid="zoi230323r22" ref-type="bibr">22</xref></sup> Only gluteal IM administration was evaluated in prior trials of tixagevimab-cilgavimab and sotrovimab.<sup><xref rid="zoi230323r14" ref-type="bibr">14</xref>,<xref rid="zoi230323r21" ref-type="bibr">21</xref>,<xref rid="zoi230323r23" ref-type="bibr">23</xref>,<xref rid="zoi230323r24" ref-type="bibr">24</xref></sup> Previously reported pharmacokinetic results from the ACTIV-2 study<sup><xref rid="zoi230323r25" ref-type="bibr">25</xref></sup> support thigh administration of this mAb combination, although the time to reach the expected effective concentration could be delayed; 300 mg IV and 600 mg IM administered in the thigh achieved equivalent concentrations by 72 hours. It is notable that given these considerations and greater convenience, studies of newer SARS-CoV-2 mAbs include thigh administration.<sup><xref rid="zoi230323r26" ref-type="bibr">26</xref></sup></p>
              <p>The virologic findings from this study complement those from the placebo-controlled phase 3 TACKLE trial of gluteal IM administration of tixagevimab-cilgavimab,<sup><xref rid="zoi230323r21" ref-type="bibr">21</xref></sup> where a reduction through day 6 in nasopharyngeal SARS-CoV-2 RNA levels was observed compared with placebo. The larger TACKLE study, which recruited unvaccinated individuals a median of 5 days from symptom onset, demonstrated a 50% reduction in progression to severe COVID-19 and death in those administered IM tixagevimab-cilgavimab vs placebo.<sup><xref rid="zoi230323r21" ref-type="bibr">21</xref></sup> In TACKLE, efficacy against COVID-19 progression decreased from 88% when administered within 3 days of symptom onset to 67% within 5 days of symptoms. More than 55% of both ACTIV-2 IM and IV groups enrolled more than 5 days after symptom onset, and 25% after more than 7 days.</p>
              <p>We found a significant decline in SARS-CoV-2 RNA from baseline to day 3 in the post hoc analysis for IV but not IM tixagevimab-cilgavimab compared with placebo. It is possible the more rapid achievement of effective mAb concentrations with IV compared with IM administration could also provide greater protection from disease progression, depending on the timing of treatment. Drugs with demonstrated antiviral effect have consistently shown effect on hospitalizations, while clinical benefits have also been observed in the absence of effect on nasopharyngeal RNA.<sup><xref rid="zoi230323r3" ref-type="bibr">3</xref>,<xref rid="zoi230323r27" ref-type="bibr">27</xref>,<xref rid="zoi230323r28" ref-type="bibr">28</xref></sup> Drugs with antiviral effect have also failed to shorten symptoms in lower-risk populations.<sup><xref rid="zoi230323r29" ref-type="bibr">29</xref></sup> In studies comparing IV vs IM or subcutaneous administration of 2 other anti‚ÄìSARS-CoV-2 mAbs, lower point estimates for hospitalizations were observed for IV administration, although outcomes were not statistically different from the alternate route of administration.<sup><xref rid="zoi230323r24" ref-type="bibr">24</xref>,<xref rid="zoi230323r25" ref-type="bibr">25</xref>,<xref rid="zoi230323r30" ref-type="bibr">30</xref></sup></p>
              <sec id="H2-9-ZOI230323">
                <title>Limitations</title>
                <p>While the randomized placebo-controlled design, standardized outcome measures, and diverse population are strengths of our study, there are limitations. Foremost, phase 2 studies within ACTIV-2 were powered for the primary virologic end point and were not designed to detect differences in rates of hospitalization or death. As age is a major risk factor for COVID-19 progression, the younger age of participants in this study could have contributed to lower hospitalization rates, further limiting evaluation of this end point. Although only higher-risk participants were eligible for the IV group, and the effect of the study agent on COVID-19 progression appeared stronger in that group, which was older than the IM group, the hospitalization rate across the IM and IV placebo arms was similar. Enrollment into the IV group was truncated, which reduced statistical power and our ability to detect signals in the primary analyses.</p>
                <p>Enrollment into ACTIV-2 occurred prior to the widespread circulation of the Delta variant, and this mAb combination has reduced neutralization against Omicron subvariants.<sup><xref rid="zoi230323r19" ref-type="bibr">19</xref>,<xref rid="zoi230323r31" ref-type="bibr">31</xref></sup> Doses for these trials were selected for the ancestral SARS-CoV-2 strain. However, short delays to reach effective concentration after IM administration could impact efficacy, and this could be compounded by the longer time from symptom onset to enrollment. The potential drawbacks of longer time to effective concentration with IM administration could be offset by the ease of administration, which could alleviate the access bottlenecks and inequities observed with IV COVID-19 treatments.<sup><xref rid="zoi230323r32" ref-type="bibr">32</xref>,<xref rid="zoi230323r33" ref-type="bibr">33</xref></sup></p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI230323">
              <title>Conclusions</title>
              <p>Results of these 2 randomized clinical trials indicate that tixagevimab-cilgavimab administered IM to the thigh was safe but neither IM nor IV treatment had significant effects on measured symptom outcomes. An antiviral effect of tixagevimab-cilgavimab was demonstrated in the primary virologic analysis for IM and other analyses in the truncated IV study. There were numerically fewer hospitalizations with receipt of tixagevimab-cilgavimab.</p>
              <p>Therapeutic options for COVID-19 remain limited. At present, there are no mAbs available with activity against the circulating SARS-CoV-2 variants. Our findings support IM thigh administration of mAbs, a route that should be considered in development of mAbs for SARS-CoV-2 infection.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI230323">
              <title>References</title>
              <ref id="zoi230323r1">
                <label>1</label>
                <mixed-citation publication-type="webpage">National Institutes of Health. Coronavirus disease <year>2019</year> (COVID-19) treatment guidelines. Updated December 28, 2022. Accessed March 4, 2022. <ext-link xlink:href="https://www.covid19treatmentguidelines.nih.gov/" ext-link-type="uri">https://www.covid19treatmentguidelines.nih.gov/</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230323r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dougan</surname><given-names>M</given-names></string-name>, <string-name><surname>Nirula</surname><given-names>A</given-names></string-name>, <string-name><surname>Azizad</surname><given-names>M</given-names></string-name>, <etal/>; <collab>BLAZE-1 Investigators</collab></person-group>. <article-title>Bamlanivimab plus etesevimab in mild or moderate COVID-19</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>(<issue>15</issue>):<fpage>1382</fpage>-<lpage>1392</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2102685</pub-id><?supplied-pmid 34260849?><pub-id pub-id-type="pmid">34260849</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gupta</surname><given-names>A</given-names></string-name>, <string-name><surname>Gonzalez-Rojas</surname><given-names>Y</given-names></string-name>, <string-name><surname>Juarez</surname><given-names>E</given-names></string-name>, <etal/>; <collab>COMET-ICE Investigators</collab></person-group>. <article-title>Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>(<issue>21</issue>):<fpage>1941</fpage>-<lpage>1950</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2107934</pub-id><?supplied-pmid 34706189?><pub-id pub-id-type="pmid">34706189</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hammond</surname><given-names>J</given-names></string-name>, <string-name><surname>Leister-Tebbe</surname><given-names>H</given-names></string-name>, <string-name><surname>Gardner</surname><given-names>A</given-names></string-name>, <etal/>; <collab>EPIC-HR Investigators</collab></person-group>. <article-title>Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>(<issue>15</issue>):<fpage>1397</fpage>-<lpage>1408</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2118542</pub-id><?supplied-pmid 35172054?><pub-id pub-id-type="pmid">35172054</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jayk Bernal</surname><given-names>A</given-names></string-name>, <string-name><surname>Gomes da Silva</surname><given-names>MM</given-names></string-name>, <string-name><surname>Musungaie</surname><given-names>DB</given-names></string-name>, <etal/></person-group>. <article-title>Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>(<issue>6</issue>):<fpage>509</fpage>-<lpage>520</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2116044</pub-id><?supplied-pmid 34914868?><pub-id pub-id-type="pmid">34914868</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Weinreich</surname><given-names>DM</given-names></string-name>, <string-name><surname>Sivapalasingam</surname><given-names>S</given-names></string-name>, <string-name><surname>Norton</surname><given-names>T</given-names></string-name>, <etal/>; <collab>Trial Investigators</collab></person-group>. <article-title>REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>3</issue>):<fpage>238</fpage>-<lpage>251</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2035002</pub-id><?supplied-pmid 33332778?><pub-id pub-id-type="pmid">33332778</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Weinreich</surname><given-names>DM</given-names></string-name>, <string-name><surname>Sivapalasingam</surname><given-names>S</given-names></string-name>, <string-name><surname>Norton</surname><given-names>T</given-names></string-name>, <etal/>; <collab>Trial Investigators</collab></person-group>. <article-title>REGEN-COV antibody combination and outcomes in outpatients with COVID-19</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>(<issue>23</issue>):<elocation-id>e81</elocation-id>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2108163</pub-id><?supplied-pmid 34587383?><pub-id pub-id-type="pmid">34587383</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Levin</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ustianowski</surname><given-names>A</given-names></string-name>, <string-name><surname>De Wit</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>LB5: PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults</article-title>. <source>Open Forum Infect Dis</source>. <year>2021</year>;<volume>8</volume>(<issue>suppl 1</issue>):<fpage>S810</fpage>-<lpage>S810</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ofid/ofab466.1646</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r9">
                <label>9</label>
                <mixed-citation publication-type="webpage"><person-group><collab>US Food and Drug Administration</collab></person-group>. Evusheld healthcare providers factsheet: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab). Revised January <year>2023</year>. Accessed February 18, 2023. <ext-link xlink:href="https://www.fda.gov/media/154701/download" ext-link-type="uri">https://www.fda.gov/media/154701/download</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230323r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Saylor</surname><given-names>C</given-names></string-name>, <string-name><surname>Dadachova</surname><given-names>E</given-names></string-name>, <string-name><surname>Casadevall</surname><given-names>A</given-names></string-name></person-group>. <article-title>Monoclonal antibody-based therapies for microbial diseases</article-title>. <source>Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>suppl 6</issue>):<fpage>G38</fpage>-<lpage>G46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.09.105</pub-id><?supplied-pmid 20006139?><pub-id pub-id-type="pmid">20006139</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Casadevall</surname><given-names>A</given-names></string-name></person-group>. <article-title>The case for pathogen-specific therapy</article-title>. <source>Expert Opin Pharmacother</source>. <year>2009</year>;<volume>10</volume>(<issue>11</issue>):<fpage>1699</fpage>-<lpage>1703</lpage>. doi:<pub-id pub-id-type="doi">10.1517/14656560903066837</pub-id><?supplied-pmid 19558338?><pub-id pub-id-type="pmid">19558338</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><collab>Group I-RS</collab></person-group>. <article-title>Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants</article-title>. <source>Pediatrics</source>. <year>1998</year>;<volume>102</volume>(<issue>3</issue>):<fpage>531</fpage>-<lpage>537</lpage>. doi:<pub-id pub-id-type="doi">10.1542/peds.102.3.531</pub-id><?supplied-pmid 9724660?><pub-id pub-id-type="pmid">9724660</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fan</surname><given-names>P</given-names></string-name>, <string-name><surname>Chi</surname><given-names>X</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors</article-title>. <source>MAbs</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>1742457</elocation-id>. doi:<pub-id pub-id-type="doi">10.1080/19420862.2020.1742457</pub-id><?supplied-pmid 32213108?><pub-id pub-id-type="pmid">32213108</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Loo</surname><given-names>Y-M</given-names></string-name>, <string-name><surname>McTamney</surname><given-names>PM</given-names></string-name>, <string-name><surname>Arends</surname><given-names>RH</given-names></string-name>, <etal/></person-group>. <article-title>The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans</article-title>. <source>Sci Transl Med</source>. <year>2022</year>;<volume>14</volume>(<issue>635</issue>):<elocation-id>eabl8124</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.abl8124</pub-id><?supplied-pmid 35076282?><pub-id pub-id-type="pmid">35076282</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Forte-Soto</surname><given-names>P</given-names></string-name>, <string-name><surname>Albayaty</surname><given-names>M</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Safety, Tolerability and pharmacokinetics of half-life extended SARS-CoV-2 neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy adults</article-title>. <source>J Infect Dis</source>. Published online January 23, <year>2023</year>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiad014</pub-id><?supplied-pmid 36683419?><pub-id pub-id-type="pmid">36683419</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>VanBlargan</surname><given-names>LA</given-names></string-name>, <string-name><surname>Errico</surname><given-names>JM</given-names></string-name>, <string-name><surname>Halfmann</surname><given-names>PJ</given-names></string-name>, <etal/></person-group>. <article-title>An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>(<issue>3</issue>):<fpage>490</fpage>-<lpage>495</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01678-y</pub-id><?supplied-pmid 35046573?><pub-id pub-id-type="pmid">35046573</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dejnirattisai</surname><given-names>W</given-names></string-name>, <string-name><surname>Huo</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>D</given-names></string-name>, <etal/>; <collab>OPTIC Consortium</collab>; <collab>ISARIC4C Consortium</collab></person-group>. <article-title>SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses</article-title>. <source>Cell</source>. <year>2022</year>;<volume>185</volume>(<issue>3</issue>):<fpage>467</fpage>-<lpage>484.e15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2021.12.046</pub-id><?supplied-pmid 35081335?><pub-id pub-id-type="pmid">35081335</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Iketani</surname><given-names>S</given-names></string-name>, <string-name><surname>Guo</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2</article-title>. <source>Nature</source>. <year>2022</year>;<volume>602</volume>(<issue>7898</issue>):<fpage>676</fpage>-<lpage>681</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-021-04388-0</pub-id><?supplied-pmid 35016198?><pub-id pub-id-type="pmid">35016198</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r19">
                <label>19</label>
                <mixed-citation publication-type="webpage"><person-group><collab>National Center for Advancing Translational Sciences</collab></person-group>. SARS-CoV-2 variants and therapeutics: therapeutic activity explorer. Updated March 9, <year>2023</year>. Accessed March 1, 2022. <ext-link xlink:href="https://opendata.ncats.nih.gov/variant/activity/singlemutationvariant" ext-link-type="uri">https://opendata.ncats.nih.gov/variant/activity/singlemutationvariant</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230323r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chew</surname><given-names>KW</given-names></string-name>, <string-name><surname>Moser</surname><given-names>C</given-names></string-name>, <string-name><surname>Daar</surname><given-names>ES</given-names></string-name>, <etal/>; <collab>ACTIV-2/A5401 Study Team</collab></person-group>. <article-title>Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>4931</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-022-32551-2</pub-id><?supplied-pmid 35995785?><pub-id pub-id-type="pmid">35995785</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Montgomery</surname><given-names>H</given-names></string-name>, <string-name><surname>Hobbs</surname><given-names>FDR</given-names></string-name>, <string-name><surname>Padilla</surname><given-names>F</given-names></string-name>, <etal/>; <collab>TACKLE study group</collab></person-group>. <article-title>Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Respir Med</source>. <year>2022</year>;<volume>10</volume>(<issue>10</issue>):<fpage>985</fpage>-<lpage>996</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(22)00180-1</pub-id><?supplied-pmid 35688164?><pub-id pub-id-type="pmid">35688164</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zuidema</surname><given-names>J</given-names></string-name>, <string-name><surname>Pieters</surname><given-names>F</given-names></string-name>, <string-name><surname>Duchateau</surname><given-names>G</given-names></string-name></person-group>. <article-title>Release and absorption rate aspects of intramuscularly injected pharmaceuticals</article-title>. <source>Int J Pharm</source>. <year>1988</year>;<volume>47</volume>(<issue>1-3</issue>):<fpage>1</fpage>-<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0378-5173(88)90209-8</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Levin</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ustianowski</surname><given-names>A</given-names></string-name>, <string-name><surname>De Wit</surname><given-names>S</given-names></string-name>, <etal/>; <collab>PROVENT Study Group</collab></person-group>. <article-title>Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>(<issue>23</issue>):<fpage>2188</fpage>-<lpage>2200</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2116620</pub-id><?supplied-pmid 35443106?><pub-id pub-id-type="pmid">35443106</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Shapiro</surname><given-names>AE</given-names></string-name>, <string-name><surname>Sarkis</surname><given-names>E</given-names></string-name>, <string-name><surname>Acloque</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Intramuscular versus intravenous SARS-CoV-2 neutralising antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomised non-inferiority clinical trial</article-title>. <source>Lancet</source>. Published online May 20, 2022. doi:<pub-id pub-id-type="doi">10.2139/ssrn.4111060</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bender Ignacio</surname><given-names>RA</given-names></string-name>, <string-name><surname>Wohl</surname><given-names>DA</given-names></string-name>, <string-name><surname>Arends</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection</article-title>. <source>Clin Pharmacol Ther</source>. <year>2022</year>;<volume>112</volume>(<issue>6</issue>):<fpage>1207</fpage>-<lpage>1213</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.2706</pub-id><?supplied-pmid 35797235?><pub-id pub-id-type="pmid">35797235</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r26">
                <label>26</label>
                <mixed-citation publication-type="webpage">Study Understanding Pre-exposure Prophylaxis of Novel Antibodies (SUPERNOVA). ClinicalTrials.gov identifier: NCT05648110. Accessed January 31, 2023. <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT05648110" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT05648110</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230323r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gottlieb</surname><given-names>RL</given-names></string-name>, <string-name><surname>Vaca</surname><given-names>CE</given-names></string-name>, <string-name><surname>Paredes</surname><given-names>R</given-names></string-name>, <etal/>; <collab>GS-US-540-9012 (PINETREE) Investigators</collab></person-group>. <article-title>Early remdesivir to prevent progression to severe COVID-19 in outpatients</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>(<issue>4</issue>):<fpage>305</fpage>-<lpage>315</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2116846</pub-id><?supplied-pmid 34937145?><pub-id pub-id-type="pmid">34937145</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Parienti</surname><given-names>JJ</given-names></string-name>, <string-name><surname>de Grooth</surname><given-names>HJ</given-names></string-name></person-group>. <article-title>Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients with COVID-19</article-title>. <source>J Antimicrob Chemother</source>. <year>2022</year>;<volume>77</volume>(<issue>7</issue>):<fpage>2038</fpage>-<lpage>2039</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkac104</pub-id><?supplied-pmid 35380667?><pub-id pub-id-type="pmid">35380667</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r29">
                <label>29</label>
                <mixed-citation publication-type="webpage"><person-group><collab>Pfizer</collab></person-group>. Pfizer reports additional data on PAXLOVID‚Ñ¢ supporting upcoming new drug application submission to US FDA. June 14, 2022. Accessed January 30, 2023. <ext-link xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting" ext-link-type="uri">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230323r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McCreary</surname><given-names>EK</given-names></string-name>, <string-name><surname>Bariola</surname><given-names>JR</given-names></string-name>, <string-name><surname>Wadas</surname><given-names>RJ</given-names></string-name>, <etal/></person-group>. <article-title>Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>4</issue>):<elocation-id>e226920</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.6920</pub-id><?supplied-pmid 35412625?><pub-id pub-id-type="pmid">35412625</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r31">
                <label>31</label>
                <mixed-citation publication-type="preprint"><person-group><string-name><surname>Yamasoba</surname><given-names>D</given-names></string-name>, <string-name><surname>Kosugi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kimura</surname><given-names>I</given-names></string-name>, <etal/></person-group>. <article-title>Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies</article-title>. <source>bioRxiv</source>. Preprint posted online May 3, 2022. doi:<pub-id pub-id-type="doi">10.1101/2022.05.03.490409</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hamer</surname><given-names>MK</given-names></string-name>, <string-name><surname>Alasmar</surname><given-names>A</given-names></string-name>, <string-name><surname>Kwan</surname><given-names>BM</given-names></string-name>, <string-name><surname>Wynia</surname><given-names>MK</given-names></string-name>, <string-name><surname>Ginde</surname><given-names>AA</given-names></string-name>, <string-name><surname>DeCamp</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Referrals, access, and equity of monoclonal antibodies for outpatient COVID-19: a qualitative study of clinician perspectives</article-title>. <source>Medicine (Baltimore)</source>. <year>2022</year>;<volume>101</volume>(<issue>50</issue>):<elocation-id>e32191</elocation-id>. doi:<pub-id pub-id-type="doi">10.1097/MD.0000000000032191</pub-id><?supplied-pmid 36550877?><pub-id pub-id-type="pmid">36550877</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230323r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Drittel</surname><given-names>D</given-names></string-name>, <string-name><surname>Abdel-Azim</surname><given-names>H</given-names></string-name>, <string-name><surname>Chernovolenko</surname><given-names>D</given-names></string-name>, <string-name><surname>Godbout</surname><given-names>B</given-names></string-name>, <string-name><surname>Duroseau</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Comparing patient demographics in those receiving monoclonal antibody therapy for SARS-CoV-2 in the emergency department versus outpatient infusion centers: a lesson in health care access during a global pandemic</article-title>. <source>Ann Emerg Med</source>. <year>2021</year>;<volume>78</volume>(<issue>2</issue>):<fpage>S42</fpage>-<lpage>S43</lpage>. Abstract 90. doi:<pub-id pub-id-type="doi">10.1016/j.annemergmed.2021.07.092</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI230323-1">
              <supplementary-material id="note-ZOI230323-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol and Statistical Analysis Plan
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2310039-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eMethods 1.</bold> Participant Enrollment and Study Analysis</p>
                  <p><bold>eFigure.</bold> CONSORT Diagram</p>
                  <p><bold>eTable 1.</bold> Clinical Outcomes Amongst Persons Randomized to Receive Tixagevimab-Cilgavimab, 600 mg IM or 300 mg IV, or Placebo</p>
                  <p><bold>eTable 2.</bold> Clinical Outcomes Stratified by Symptom Duration Prior to Randomization</p>
                  <p><bold>eTable 3.</bold> Number and Proportion of Participants With SARS-CoV-2 RNA Levels Below and at or above the LLOQ From NP Swabs by Duration of Symptoms Prior to Enrollment (‚â§ 5 or &gt;5 d), Amongst Those in the Tixagevimab-Cilgavimab, 600 mg IM and 300 mg IV, Groups</p>
                  <p><bold>eTable 4.</bold> Change in NP RNA From Day 0 to Day 3 Among Those With NP RNA at Day 0 Greater Than LLOQ</p>
                  <p><bold>eTable 5.</bold> Number and Proportion of Participants With Unquantifiable SARS-CoV-2 RNA Levels From Participant Self-collected Anterior Nasal (AN) Swabs Amongst Persons in the Tixagevimab-Cilgavimab, 600 mg IM and 300 mg IV, Groups</p>
                  <p><bold>eTable 6.</bold> Number of Participants With Adverse Events Grade 2 or Higher Through Day 28</p>
                  <p><bold>eTable 7.</bold> Variants Among Persons Randomized to Either IV or IM Tixagevimab-Cilgavimab or Placebo Groups</p>
                  <p><bold>eMethods 2.</bold> Site Acknowledgments</p>
                </caption>
                <media xlink:href="jamanetwopen-e2310039-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Nonauthor Collaborators
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2310039-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 4.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2310039-s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
